VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study.
Juvéderm Volite
hyaluronic acid
injectable dermal filler
skin aging
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
05
2019
accepted:
29
09
2019
entrez:
22
11
2019
pubmed:
22
11
2019
medline:
22
11
2019
Statut:
epublish
Résumé
Evaluate safety and effectiveness of VYC-12 (Juvéderm Volite; an injectable crosslinked hyaluronic acid gel designed to improve skin quality attributes such as surface smoothness and hydration) for facial intradermal injection. In a prospective, single-arm study, subjects with moderate/severe cheek skin roughness per Allergan Skin Roughness Scale (ASRS) received VYC-12 in the cheeks and forehead, and/or neck, with touch-up treatment to correct asymmetry 30 days later and optional repeat treatment 9 months after last treatment. The primary effectiveness measure was ASRS responder rate (percentage of cheeks with ≥1-point improvement from baseline) at month 1. Skin hydration was instrument-assessed. Of 131 subjects treated, 31 (23.7%) received touch-up treatment. ASRS responder rate was 96.2% at month 1, 76.3% at month 4, 34.9% at month 6, and 87.1% after repeat treatment. Responder rate in cheeks with severe baseline roughness was 93.8%, 83.1%, and 52.3% at months 1, 4, and 6, respectively. Skin hydration improved significantly ( VYC-12 safely and effectively improved skin smoothness up to 6 months and hydration lasting 9 months.
Identifiants
pubmed: 31749628
doi: 10.2147/CCID.S216222
pii: 216222
pmc: PMC6817835
doi:
Types de publication
Case Reports
Langues
eng
Pagination
791-798Informations de copyright
© 2019 Niforos et al.
Déclaration de conflit d'intérêts
F. Niforos, C. Leys, M. Cavallini, P. Ogilvie, M. Safa, and J. Chantrey are investigators for Allergan plc, Marlow, UK. J. Chantrey reports personal fee from Allergan as a teaching consultant, during the conduct of the study and outside the submitted work. A. Marx and S. Abrams are employees of Allergan plc, Irvine, CA. R. Hopfinger was an employee of Allergan plc, Irvine, CA at the time of this study. The authors report no other conflicts of interest in this work.
Références
Dermatol Surg. 2016 Oct;42 Suppl 1:S219-S226
pubmed: 27661744
Br J Dermatol. 1990 Apr;122 Suppl 35:5-11
pubmed: 2186786
Arch Plast Surg. 2015 May;42(3):282-7
pubmed: 26015882
Plast Reconstr Surg. 2015 Nov;136(5 Suppl):188S-195S
pubmed: 26441098
Int J Cosmet Sci. 2008 Oct;30(5):323-32
pubmed: 18822037
Dermatol Surg. 2008 May;34(5):720-6
pubmed: 18384619
Skin Res Technol. 2013 Feb;19(1):e349-55
pubmed: 22672420
Vision Res. 1998 Sep;38(17):2601-17
pubmed: 12116706
J Cosmet Dermatol. 2016 Dec;15(4):578-582
pubmed: 27401775
J Cosmet Laser Ther. 2009 Sep;11(3):169-73
pubmed: 19337944
Perception. 2016 Apr;45(4):400-8
pubmed: 26621963
J Exp Psychol Hum Percept Perform. 2012 Dec;38(6):1353-61
pubmed: 22288693
Biomed Res Int. 2015;2015:318586
pubmed: 25767806
Dermatol Surg. 2015 Aug;41(8):929-39
pubmed: 26166260
Cortex. 2013 Jan;49(1):252-65
pubmed: 22055429
Dermatol Surg. 2016 Oct;42 Suppl 1:S227-S234
pubmed: 27661745
J Dermatol Sci. 2016 Sep;83(3):174-81
pubmed: 27378089
Perception. 1995;24(10):1131-8
pubmed: 8577572
J Drugs Dermatol. 2013 Sep;12(9):990-4
pubmed: 24002145
Aesthet Surg J. 2015 Nov;35(8):1007-13
pubmed: 26508650
J Comp Psychol. 2001 Mar;115(1):92-9
pubmed: 11334223
Arch Dermatol. 2008 May;144(5):666-72
pubmed: 18490597
Plast Reconstr Surg. 2016 Mar;137(3):809-16
pubmed: 26910661
Skinmed. 2013 Sep-Oct;11(5):281-6
pubmed: 24340467
Plast Reconstr Surg Glob Open. 2015 Apr 07;3(3):e321
pubmed: 25878932
N Engl J Med. 1997 Nov 13;337(20):1419-28
pubmed: 9358139
Dermatol Surg. 2019 Jul;45(7):959-967
pubmed: 30789512